The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

Autor: Rodríguez Moncada R; Aparato Digestivo, Hospital Juan Ramón Jiménez, España., Vázquez Morón JM; Aparato Digestivo, Hospital Juan Ramón Jiménez., Pallarés Manrique H; Aparato Digestivo, Hospital Juan Ramón Jiménez.
Jazyk: angličtina
Zdroj: Revista espanola de enfermedades digestivas [Rev Esp Enferm Dig] 2019 Sep; Vol. 111 (9), pp. 720-721.
DOI: 10.17235/reed.2019.5841/2018
Abstrakt: In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.
Databáze: MEDLINE